Semifluorinated compounds and their compositions

Abstract

The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

1 . A composition comprising CF 3 (CF 2 ) 5 (CH 2 ) 7 CH 3  and CF 3- (CF 2 ) 5- CH(CH 3 )—(CH 2 ) 5 —CH 3 . 
     
     
         2 . The composition according to  claim 1 , comprising at least about 80 wt % of CF 3 (CF 2 ) 5 (CH 2 ) 7 CH 3 . 
     
     
         3 . The composition according to  claim 1 , comprising up to about 25 wt % of CF 3 —(CF 2 ) 5 —CH(CH 3 )—(CH 2 ) 5 —CH 3 . 
     
     
         4 . The composition according to any preceding  claim 1  comprising about 97 wt % of CF 3 (CF 2 ) 5 (CH 2 ) 7 CH 3  and up to about 3 wt % of CF 3 —(CF 2 ) 5 —CH(CH 3 )—(CH 2 ) 5 —CH 3 . 
     
     
         5 . The composition according to  claim 1 , being formulated as a clear liquid solution. 
     
     
         6 . The composition of  claim 1 , being substantially free of:
 (a) a polymer,   (b) a perfluorinated compound, and/or   (c) a dissolved pharmacologically active ingredient.   
     
     
         7 . The composition of  claim 1 , having a dynamic viscosity of not more than 10 mPa·s, and preferably not more than 4 mPa·s, at ambient temperature and pressure. 
     
     
         8 . A method of treating a disease or condition of a patient in need of such treatment, comprising administering the composition according to  claim 1  to the patient. 
     
     
         9 . The method according to  claim 8 , wherein the composition is topically administered to a lacrimal sac, into a lower eyelid, to an eye surface, or to an ophthalmic tissue. 
     
     
         10 . The method according to  claim 8 , wherein the composition is administered up to four times per day. 
     
     
         11 . The method according to  claim 8 , wherein the disease or condition to be treated is keratoconjunctivitis sicca or a symptom or condition associated therewith, and/or Meibomian Gland Dysfunction (MGD). 
     
     
         12 . The method according to  claim 8 , wherein the composition is administered to lubricate the eye surface. 
     
     
         13 . The method according to  claim 8 , wherein the condition to be treated is corneal damage. 
     
     
         14 . A kit comprising a composition according to  claim 1  and a container for holding the composition, wherein said container comprises a dispensing means adapted for topical administration of the composition to a lacrimal sac, into a lower eyelid, to an eye surface, or to an ophthalmic tissue. 
     
     
         15 . The kit of  claim 14 , wherein the dispensing means comprises a dropper dimensions such as to dispense droplets having a volume of 8 to 15 μL. 
     
     
         16 . The composition according to  claim 1  consisting of about 97 wt % of CF 3 (CF 2 ) 5 (CH 2 ) 7 CH 3  and up to about 3 wt % of CF 3 —(CF 2 ) 5 —CH(CH 3 )—(CH 2 ) 5 —CH 3 . 
     
     
         17 . The composition according to  claim 3 , being formulated as a clear liquid solution. 
     
     
         18 . The composition of  claim 4 , being substantially free of:
 (a) a polymer,   (b) a perfluorinated compound, and/or   (c) a dissolved pharmacologically active ingredient.   
     
     
         19 . The composition of  claim 5 , being substantially free of:
 (a) a polymer,   (b) a perfluorinated compound, and/or   (c) a dissolved pharmacologically active ingredient.   
     
     
         20 . The composition according to  claim 18 , being formulated as a clear liquid solution.